Search

Your search keyword '"Gottschling, Sven"' showing total 387 results
Start Over Author "Gottschling, Sven"
387 results on '"Gottschling, Sven"'

3. Integrative medicine during the intensive phase of chemotherapy in pediatric oncology in Germany: a randomized controlled trial with 5-year follow up

Author

Seifert, Georg, Blakeslee, Sarah B., Calaminus, Gabriele, Kandil, Farid I., Barth, Andrea, Bernig, Toralf, Classen, Carl Friedrich, Corbacioglu, Selim, Föll, Jürgen, Gottschling, Sven, Gruhn, Bernd, vom Hoff-Heise, Claudia, Lode, Holger N., Martin, David, Nathrath, Michaela, Neunhoeffer, Felix, Pekrun, Arnulf, Wulff, Beate, Zuzak, Tycho, Henze, Günter, and Längler, Alfred

Published
2022
Full Text
View/download PDF

9. Nutzen und Schaden von Cannabisarzneimitteln aus Sicht von Patienten mit chronischen Schmerzen und ihren Ärzten: Eine Kohortenstudie in drei saarländischen Schmerzzentren.

Author

Böttge-Wolpers, Claudia, Bialas, Patric, Gottschling, Sven, Juckenhöfel, Stephanie, Konietzke, Dieter, Madlinger, Albrecht, Welsch, Patrick, and Häuser, Winfried

Abstract

Copyright of Der Schmerz is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2024
Full Text
View/download PDF

10. Vorwort

Author

Welsch, Katja, primary and Gottschling, Sven, additional

Published
2021
Full Text
View/download PDF

15. Cannabis use disorder in patients with chronic pain: overestimation and underestimation in a cross-sectional observational study in 3 German pain management centres

Author

Bialas, Patric, primary, Böttge-Wolpers, Claudia, additional, Fitzcharles, Mary-Ann, additional, Gottschling, Sven, additional, Konietzke, Dieter, additional, Juckenhöfel, Stephanie, additional, Madlinger, Albrecht, additional, Welsch, Patrick, additional, and Häuser, Winfried, additional

Published
2022
Full Text
View/download PDF

23. Safety Considerations in Cannabinoid-Based Medicine

Author

Gottschling, Sven, Ayonrinde, Oyedeji, Bhaskar, Arun, Blockman, Marc, D’Agnone, Oscar, Schecter, Danial, Suárez Rodríguez, Luis David, Yafai, Sherry, and Cyr, Claude

Subjects
cannabis, safety, cannabidiol, Review, Δ9-tetrahydrocannabinol, cannabinoid
Abstract

Cannabinoids are a diverse class of chemical compounds that are increasingly recognized as potential therapeutic options for a range of conditions. While many studies and reviews of cannabinoids focus on efficacy, safety is much less well reported. Overall assessment of the safety of cannabinoid-based medicines is confounded by confusion with recreational cannabis use as well as different study designs, indications, dosing, and administration methods. However, clinical studies in registered products are increasingly available, and this article aims to discuss and clarify what is known regarding the safety profiles of cannabinoid-based medicines, focusing on the medical and clinical safety evidence and identifying areas for future research. The two most well-studied cannabinoids are Δ9-tetrahydrocannabinol (THC), or its synthetic variants (dronabinol, nabilone), and cannabidiol (CBD). Across diverse indications, dizziness and fatigue are generally the most common adverse events experienced by patients receiving THC or combined THC and CBD. Patients receiving THC may experience adverse cognitive effects and impairment in psychomotor skills, with implications for driving and some occupations, while CBD may help to lower the psychotropic effects of THC when used in combination. Studies on dependency and addiction in a medical context are limited, but have shown inconsistent findings regarding misuse potential. Generally, the recommended route of administration is oral ingestion, as smoking medicinal cannabinoid products potentially releases mutagenic and carcinogenic by-products. There are several potential drug–drug interactions and contraindications for cannabinoid-based medicines, which physicians should account for when making prescribing decisions. The available evidence shows that, as with any other class of pharmaceuticals, cannabinoid-based medicines are associated with safety risks which should be assessed in the context of potential therapeutic benefits. Each patient should be assessed on an individual basis and physicians must rely on informed, evidence-based decision-making when determining whether a cannabinoid-based medicine could be an appropriate treatment option.

Published
2020

24. Additional file 1 of Integrative medicine during the intensive phase of chemotherapy in pediatric oncology in Germany: a randomized controlled trial with 5-year follow up

Author

Seifert, Georg, Blakeslee, Sarah B., Calaminus, Gabriele, Kandil, Farid I., Barth, Andrea, Bernig, Toralf, Classen, Carl Friedrich, Corbacioglu, Selim, Föll, Jürgen, Gottschling, Sven, Gruhn, Bernd, vom Hoff-Heise, Claudia, Lode, Holger N., Martin, David, Nathrath, Michaela, Neunhoeffer, Felix, Pekrun, Arnulf, Wulff, Beate, Zuzak, Tycho, Henze, Günter, and Längler, Alfred

Subjects
Data_FILES
Abstract

Additional file 1.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results